Understanding CYP3A4 and P‐gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib

• Principais autores: Christine Bowman (Autor), Michael Dolton (Autor), Fang Ma (Autor), Sravanthi Cheeti (Autor), Denison Kuruvilla (Autor), Rucha Sane (Autor), Nastya Kassir (Autor), Yuan Chen (Autor)
• Formato: Livro
• Publicado em: Wiley, 2024-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Pralsetinib, a potent and selective inhibitor of oncogenic RET fusion and RET mutant proteins, is a substrate of the drug metabolizing enzyme CYP3A4 and a substrate of the efflux transporter P‐gp based on in vitro data. Therefore, its pharmacokinetics (PKs) may be affected by co‐administrat...